Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy

The National Cancer Institute randomized trial

Matthew M. Poggi, David N. Danforth, Linda C. Sciuto, Sharon L. Smith, Seth M. Steinberg, David J. Liewehr, Cynthia Menard, Marc E Lippman, Allen S. Lichter, Rosemary M. Altemus

Research output: Contribution to journalArticle

383 Citations (Scopus)

Abstract

BACKGROUND. Between 1979-1987, the National Cancer Institute conducted a randomized, prospective study of mastectomy (MT) versus breast conservation therapy (BCT) in the treatment of patients with early-stage breast carcinoma. After a median potential follow-up of 18.4 years, the authors present the updated results. METHODS. After informed consent was obtained from each patient, 237 evaluable women with clinical AJCC Stage I and Stage II breast carcinoma were enrolled on an institutionally reviewed protocol and randomly assigned to undergo modified radical MT (116 patients) or BCT (121 patients), which was comprised of lumpectomy, axillary lymph node dissection, and radiation therapy. Negative surgical margins in the lumpectomy arm were not required. The 237 randomized patients were followed for a median potential follow-up of 18.4 years. The primary end-points were overall survival and disease-free survival. RESULTS. At a median follow-up of 18.4 years, there was no detectable difference with regard to overall survival between patients treated with MT and those treated with BCT (58% vs. 54%; P = 0.67 overall). Twenty-seven women in the BCT arm (22%) experienced an in-breast event. After censoring in-breast events in the BCT arm that were salvaged successfully by MT, disease-free survival also was found to be statistically similar (67% in the MT arm vs. 63% in the BCT arm; P = 0.64 overall). There was no statistically significant difference with regard to contralateral breast carcinoma between the two treatment arms (P = 0.70). CONCLUSIONS. After nearly 20 years of follow-up, there was no detectable difference in overall survival or disease-free survival in patients with early-stage breast carcinoma who were treated with MT compared with those treated with BCT. For BCT patients, long-term in-breast failures continued to occur throughout the duration of follow-up. There was no statistically significant difference in the incidence of contralateral breast carcinoma between the two treatment groups.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalCancer
Volume98
Issue number4
DOIs
StatePublished - Aug 15 2003
Externally publishedYes

Fingerprint

Segmental Mastectomy
National Cancer Institute (U.S.)
Mastectomy
Breast Neoplasms
Arm
Disease-Free Survival
Therapeutics
Breast
Survival
Modified Radical Mastectomy
Lymph Node Excision
Informed Consent
Radiotherapy
Prospective Studies

Keywords

  • Breast carcinoma
  • Conservation
  • Mastectomy
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Poggi, M. M., Danforth, D. N., Sciuto, L. C., Smith, S. L., Steinberg, S. M., Liewehr, D. J., ... Altemus, R. M. (2003). Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial. Cancer, 98(4), 697-702. https://doi.org/10.1002/cncr.11580

Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy : The National Cancer Institute randomized trial. / Poggi, Matthew M.; Danforth, David N.; Sciuto, Linda C.; Smith, Sharon L.; Steinberg, Seth M.; Liewehr, David J.; Menard, Cynthia; Lippman, Marc E; Lichter, Allen S.; Altemus, Rosemary M.

In: Cancer, Vol. 98, No. 4, 15.08.2003, p. 697-702.

Research output: Contribution to journalArticle

Poggi, MM, Danforth, DN, Sciuto, LC, Smith, SL, Steinberg, SM, Liewehr, DJ, Menard, C, Lippman, ME, Lichter, AS & Altemus, RM 2003, 'Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial', Cancer, vol. 98, no. 4, pp. 697-702. https://doi.org/10.1002/cncr.11580
Poggi, Matthew M. ; Danforth, David N. ; Sciuto, Linda C. ; Smith, Sharon L. ; Steinberg, Seth M. ; Liewehr, David J. ; Menard, Cynthia ; Lippman, Marc E ; Lichter, Allen S. ; Altemus, Rosemary M. / Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy : The National Cancer Institute randomized trial. In: Cancer. 2003 ; Vol. 98, No. 4. pp. 697-702.
@article{632ae700aaf74047ad99cd353b335871,
title = "Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial",
abstract = "BACKGROUND. Between 1979-1987, the National Cancer Institute conducted a randomized, prospective study of mastectomy (MT) versus breast conservation therapy (BCT) in the treatment of patients with early-stage breast carcinoma. After a median potential follow-up of 18.4 years, the authors present the updated results. METHODS. After informed consent was obtained from each patient, 237 evaluable women with clinical AJCC Stage I and Stage II breast carcinoma were enrolled on an institutionally reviewed protocol and randomly assigned to undergo modified radical MT (116 patients) or BCT (121 patients), which was comprised of lumpectomy, axillary lymph node dissection, and radiation therapy. Negative surgical margins in the lumpectomy arm were not required. The 237 randomized patients were followed for a median potential follow-up of 18.4 years. The primary end-points were overall survival and disease-free survival. RESULTS. At a median follow-up of 18.4 years, there was no detectable difference with regard to overall survival between patients treated with MT and those treated with BCT (58{\%} vs. 54{\%}; P = 0.67 overall). Twenty-seven women in the BCT arm (22{\%}) experienced an in-breast event. After censoring in-breast events in the BCT arm that were salvaged successfully by MT, disease-free survival also was found to be statistically similar (67{\%} in the MT arm vs. 63{\%} in the BCT arm; P = 0.64 overall). There was no statistically significant difference with regard to contralateral breast carcinoma between the two treatment arms (P = 0.70). CONCLUSIONS. After nearly 20 years of follow-up, there was no detectable difference in overall survival or disease-free survival in patients with early-stage breast carcinoma who were treated with MT compared with those treated with BCT. For BCT patients, long-term in-breast failures continued to occur throughout the duration of follow-up. There was no statistically significant difference in the incidence of contralateral breast carcinoma between the two treatment groups.",
keywords = "Breast carcinoma, Conservation, Mastectomy, Radiation therapy",
author = "Poggi, {Matthew M.} and Danforth, {David N.} and Sciuto, {Linda C.} and Smith, {Sharon L.} and Steinberg, {Seth M.} and Liewehr, {David J.} and Cynthia Menard and Lippman, {Marc E} and Lichter, {Allen S.} and Altemus, {Rosemary M.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1002/cncr.11580",
language = "English",
volume = "98",
pages = "697--702",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy

T2 - The National Cancer Institute randomized trial

AU - Poggi, Matthew M.

AU - Danforth, David N.

AU - Sciuto, Linda C.

AU - Smith, Sharon L.

AU - Steinberg, Seth M.

AU - Liewehr, David J.

AU - Menard, Cynthia

AU - Lippman, Marc E

AU - Lichter, Allen S.

AU - Altemus, Rosemary M.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - BACKGROUND. Between 1979-1987, the National Cancer Institute conducted a randomized, prospective study of mastectomy (MT) versus breast conservation therapy (BCT) in the treatment of patients with early-stage breast carcinoma. After a median potential follow-up of 18.4 years, the authors present the updated results. METHODS. After informed consent was obtained from each patient, 237 evaluable women with clinical AJCC Stage I and Stage II breast carcinoma were enrolled on an institutionally reviewed protocol and randomly assigned to undergo modified radical MT (116 patients) or BCT (121 patients), which was comprised of lumpectomy, axillary lymph node dissection, and radiation therapy. Negative surgical margins in the lumpectomy arm were not required. The 237 randomized patients were followed for a median potential follow-up of 18.4 years. The primary end-points were overall survival and disease-free survival. RESULTS. At a median follow-up of 18.4 years, there was no detectable difference with regard to overall survival between patients treated with MT and those treated with BCT (58% vs. 54%; P = 0.67 overall). Twenty-seven women in the BCT arm (22%) experienced an in-breast event. After censoring in-breast events in the BCT arm that were salvaged successfully by MT, disease-free survival also was found to be statistically similar (67% in the MT arm vs. 63% in the BCT arm; P = 0.64 overall). There was no statistically significant difference with regard to contralateral breast carcinoma between the two treatment arms (P = 0.70). CONCLUSIONS. After nearly 20 years of follow-up, there was no detectable difference in overall survival or disease-free survival in patients with early-stage breast carcinoma who were treated with MT compared with those treated with BCT. For BCT patients, long-term in-breast failures continued to occur throughout the duration of follow-up. There was no statistically significant difference in the incidence of contralateral breast carcinoma between the two treatment groups.

AB - BACKGROUND. Between 1979-1987, the National Cancer Institute conducted a randomized, prospective study of mastectomy (MT) versus breast conservation therapy (BCT) in the treatment of patients with early-stage breast carcinoma. After a median potential follow-up of 18.4 years, the authors present the updated results. METHODS. After informed consent was obtained from each patient, 237 evaluable women with clinical AJCC Stage I and Stage II breast carcinoma were enrolled on an institutionally reviewed protocol and randomly assigned to undergo modified radical MT (116 patients) or BCT (121 patients), which was comprised of lumpectomy, axillary lymph node dissection, and radiation therapy. Negative surgical margins in the lumpectomy arm were not required. The 237 randomized patients were followed for a median potential follow-up of 18.4 years. The primary end-points were overall survival and disease-free survival. RESULTS. At a median follow-up of 18.4 years, there was no detectable difference with regard to overall survival between patients treated with MT and those treated with BCT (58% vs. 54%; P = 0.67 overall). Twenty-seven women in the BCT arm (22%) experienced an in-breast event. After censoring in-breast events in the BCT arm that were salvaged successfully by MT, disease-free survival also was found to be statistically similar (67% in the MT arm vs. 63% in the BCT arm; P = 0.64 overall). There was no statistically significant difference with regard to contralateral breast carcinoma between the two treatment arms (P = 0.70). CONCLUSIONS. After nearly 20 years of follow-up, there was no detectable difference in overall survival or disease-free survival in patients with early-stage breast carcinoma who were treated with MT compared with those treated with BCT. For BCT patients, long-term in-breast failures continued to occur throughout the duration of follow-up. There was no statistically significant difference in the incidence of contralateral breast carcinoma between the two treatment groups.

KW - Breast carcinoma

KW - Conservation

KW - Mastectomy

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0042071601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042071601&partnerID=8YFLogxK

U2 - 10.1002/cncr.11580

DO - 10.1002/cncr.11580

M3 - Article

VL - 98

SP - 697

EP - 702

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -